Cara Therapeutics | CARA - Cost Of Sales


Cara Therapeutics reported $0 in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Assertio Holdings USD 8.89M 2.29M Jun/2024
Cara Therapeutics USD 0 0 Mar/2025
Cassava Sciences USD 3.96M 1.16M Sep/2025
Chugai Pharma JPY 92.79B 5.23B Mar/2026
Cipla INR 26.32B 2.79B Mar/2026
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 3.54M 1.89M Dec/2025
CSL USD 3.87B 2.08B Dec/2025
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
J&J USD 8.07B 103M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Pacira USD 50.74M 3.89M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
RedHill Biopharma USD 702K 0 Jun/2024
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024